Introduction: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the US and EU to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated ...
Introduction: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (US and EU) to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA;...
INTRODUCTION: Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, significantly decreased excessive sleepiness in a randomized, double-blind, placebo-controlled study of...